Treatment and outcome in patients with ocular Behçet's disease manifesting central nervous system involvement Kentaroh Kamata 1 , Hiroshi Goto 1 , Takeshi Matsuzawa 1 , Tohru Fukai 1 , Jun-ichi Sakai 1 , Masahiko Usui 1 , Norioki Tsuboi 2 1Dept of Ophthalmol, Tokyo Med Coll 2Third Dept of Internal Med, Tokyo Med Coll pp.851-854
Published Date 1998/5/15
DOI https://doi.org/10.11477/mf.1410905872
  • Abstract
  • Look Inside

We reviewed 99 cases of Behçet's disease who manifested central nervous system (CNS) symptoms during the course of treatment. Systemic cyclosporine A was administered to 22 patients, of whom 4 developed CNS symptoms. Only one out of 77 patients treated with other medications developed CNS symptoms. The difference was significant, suggesting that cyclosporine A may promote CNS manifestations in Behçet's disease. After onset of CNS symptoms, cyclosporine A was discontinued immediately and was substituted by systemic corticosteroid. All the cases showed improvement in neurological symptoms and decrease in the frequency of ocular inflammatory attacks. Visual acuity improved in only one eye.

Copyright © 1998, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院